Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-08-01Clinical Trial Update: Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 2]
Phase 2 trial of vincristine sulfate liposome for relapsed or refractory acute myeloid leukemia has been terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2019-07-23Clinical Trial Update: Decitabine Combined With Unrelated Cord Blood Transplantation for Elderly Patients With AML [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating decitabine with unrelated cord blood transplantation in elderly patients with acute myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2019-07-23Clinical Trial Update: A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005) [Phase 1]
Phase 1 dose-exploration trial of Birabresib (MK-8628) in selected hematologic malignancies (AML variants and DLBCL) has been terminated wit…
-
FDA approval · 2019-07-22FDA Approved: AZACITIDINE — Supplemental Application (Accord Healthcare Inc.)
FDA approved Accord Healthcare Inc.'s supplemental application for azacitidine.
-
CLINICAL_TRIALS trial_result · 2019-07-16Clinical Trial Update: A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients [Phase 2]
Phase 2 clinical trial update for SKLB1028 Capsule in recurrence/refractory acute myeloid leukemia.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-07-16Clinical Trial Update: Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) [Phase 1, Phase 2]
A clinical trial update for sapacitabine in acute myeloid leukemia and myelodysplastic syndromes (Phase 1/Phase 2).
-
CLINICAL_TRIALS trial_result · 2019-07-09Clinical Trial Update: A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML) [Phase 2]
Phase 2 clinical trial update for GRNVAC1 active immunotherapy in acute myeloid leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2019-06-28Clinical Trial Update: A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML) [Phase 1]
Phase I dose-escalation study of GSK2879552 in subjects with acute myeloid leukemia was terminated early; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-06-26Clinical Trial Update: Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes [Phase 1, Phase 2]
Phase 1/2 trial evaluating a combination including filgrastim, cladribine, cytarabine, and mitoxantrone in newly diagnosed or relapsed/refra…
-
CLINICAL_TRIALS trial_result · 2019-06-17Clinical Trial Update: A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]
Phase 1/2 trial evaluating sequential decitabine with cytarabine in children with relapsed or refractory acute myeloid leukemia; study termi…
-
CLINICAL_TRIALS trial_result · 2019-06-11Clinical Trial Update: A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 2]
Phase 2 trial update for LY2181308 Sodium in relapsed or refractory acute myeloid leukemia has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-06-10Clinical Trial Update: Decitabine Based Chemotherapy Followed by Haploidentical Lymphocyte Infusion for Elderly Patients With AML [Phase 2]
Phase 2 trial evaluating decitabine-based chemotherapy followed by haploidentical lymphocyte infusion in elderly AML patients has completed.
-
CLINICAL_TRIALS trial_result · 2019-06-07Clinical Trial Update: A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC [Phase 3]
Phase 3 trial evaluating azacitidine in patients with intermediate/high-risk myelodysplastic syndromes and AML with myelodysplasia-related c…
-
FDA approval · 2019-05-29FDA Approved: XOSPATA — Supplemental Application (Astellas Pharma US, Inc.)
The FDA approved a supplemental application for XOSPATA (gilteritinib) submitted by Astellas Pharma US, Inc., resulting in changes to the pr…
-
FDA approval · 2019-05-22FDA Approved: DECITABINE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for DECITABINE, submitted by Sun Pharmaceutical Industries, Inc. This action updates the regulatory …
-
CLINICAL_TRIALS trial_result · 2019-05-22Clinical Trial Update: Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 2]
Phase 2 trial evaluating decitabine with total-body irradiation followed by donor bone marrow transplant and cyclophosphamide for relapsed o…
-
CLINICAL_TRIALS trial_result · 2019-05-17Clinical Trial Update: Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML [Phase 1, Phase 2]
Clinical trial update on GMI-1271 in combination with chemotherapy for acute myeloid leukemia (AML) completed Phase 1/2 studies to assess sa…
-
CLINICAL_TRIALS trial_result · 2019-05-10Clinical Trial Update: Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML) [Phase 1, Phase 2]
Phase 1/2 clinical trial of plerixafor and clofarabine as frontline therapy in elderly AML patients; trial terminated with posted results in…
-
CLINICAL_TRIALS trial_result · 2019-05-07Clinical Trial Update: CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR [NA]
Clinical trial update for NK cell therapy in AML patients not in complete remission; the study is terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2019-05-06Clinical Trial Update: Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) [Phase 2]
Phase 2 trial evaluating dasatinib for myeloproliferative disorders; the study has completed and results were posted in 2019.
-
FDA approval · 2019-05-02FDA Approved: TIBSOVO — Supplemental Application (Servier Pharmaceutical LLC)
The FDA approved a supplemental application for TIBSOVO (ivosidenib) submitted by Servier Pharmaceutical LLC.
-
CLINICAL_TRIALS trial_result · 2019-05-01Clinical Trial Update: Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies [Phase 2]
Phase 2 clinical trial evaluating BL-8040 for mobilizing donor hematopoietic stem cells to enable allogeneic transplantation in patients wit…
-
CLINICAL_TRIALS trial_result · 2019-04-23Clinical Trial Update: DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes [Phase 1, Phase 2]
Clinical trial update for DT388IL3 fusion protein in acute myeloid leukemia and myelodysplastic syndromes (Phase 1/2) completed with results…
-
FDA approval · 2019-04-18FDA Approved: BUSULFAN — Original Application (Armas Pharmaceuticals Inc.)
FDA approved a generic Busulfan from Armas Pharmaceuticals Inc. under ANDA210931, enabling a generic formulation.
-
CLINICAL_TRIALS trial_result · 2019-04-16Clinical Trial Update: Study of Palbociclib in MLL-rearranged Acute Leukemias [Phase 1, Phase 2]
A clinical trial investigating palbociclib in MLL-rearranged acute leukemias (AML and ALL) across Phase 1 and Phase 2 ongoing with currently…